Envestnet Asset Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Envestnet Asset Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-12,021	Closed	-$223K	–	4228
2023 Q3	$223K	Buy	+12,021	New	+$136K	﹤0.01%	3690
2020 Q1	–	Sell	-2,415	Closed	-$299K	–	3177
2019 Q4	$299K	Buy	+2,415	New	+$216K	﹤0.01%	2729
2015 Q2	–	Sell	-1,393	Closed	-$393K	–	2276
2015 Q1	$393K	Buy	+1,393	New	+$302K	﹤0.01%	1659
2014 Q4	–	Sell	-2	Closed	–	–	2753
2014 Q3	$0	Hold	2	–	–	﹤0.01%	2887
2014 Q2	$0	Hold	2	–	–	﹤0.01%	2833
2014 Q1	$1K	Buy	+2	New	+$675	﹤0.01%	2472

Envestnet Asset Management's ICPT Position: Q4 2023 in Review

Envestnet Asset Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 12,021 shares — an estimated $223K sold.

Envestnet Asset Management first reported a position in ICPT in Q1 2014 and held it in 6 quarters. The position peaked at $393K in Q1 2015. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.

Envestnet Asset Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
Envestnet Asset Management sold 12,021 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $223K.
Envestnet Asset Management first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2014 and held it in 6 quarters.
Envestnet Asset Management's Intercept Pharmaceuticals, Inc. position peaked at $393K in Q1 2015.
0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.

Based on Envestnet Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.